IRCT20200407046981N22招募中未知
Comparative Bioequivalence Study of the Ursodeoxycholic acid 300-mg Capsule Produced by Ahran Tejarat Pharmaceutical Company compared to Ursoflor® by So Se PHARM.
Ahran Tejarat pharmaceutical Co0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 50 years（—）
- 性别
- Male
入选标准
- •The weight limit of each volunteer should be between 60 and 100 kg.
- •All volunteers must be non-smokers.
- •They must be healthy in terms of liver, kidney, respiratory system, mental and other general health characteristics that will be assessed.
- •Candidates who have consented to the consent form.
排除标准
- •Known hypersensitivity or idiosyncratic reaction to Ursodeoxycholic acid or any ingredients.
- •Subjects with BP = 90/60 mm/Hg or BP = 140/90 mm/Hg.
- •Regular smoker who smokes more than ten cigarettes daily.
- •Taking any medicine during two weeks before dosing.
研究者
相似试验
尚未招募
不适用
Study of absorption and elimination rate of Ursodeoxycholic acid 300-mg Capsule in comparison with Ursodeoxycholic acid brand Capsule (Ursobil®).IRCT20200407046981N41Modava pharmaceutical company24
尚未招募
不适用
rsodeoxycholic acid in cholelithiasisIRCT20120624010104N7Ahran Tejarat Pharmaceutical Company24
招募中
Unknown
Bioequivalence study of 300 mg ursodeoxycholic acid capsulesIn the present study, no disease was investigated..IRCT20230222057495N5Chemidarou Pharmaceutical Company24
招募中
Unknown
Investigating the in vivo bioequivalence of Ursodeoxycholic acid 300 mg capsuleIn the present study, the products will be administered to healthy volunteers..IRCT20210519051345N64Tabriz University of Medical Sciences24
尚未招募
不适用
Bioequivalence Study of Ursodeoxycholic acidCondition 1: Bioequivalence. Condition 2: Bioequivalence.IRCT20110523006565N2Kermanshah University of Medical Sciences24